Generative AI use cases in medical technology: Mapping high-value opportunities across the operating model

Medical technology is becoming a natural proving ground for generative and agentic AI, where data-rich workflows, regulated documentation, and repeatable decisions create clear opportunities for measurable impact. Product teams maintain design records, quality teams review complaints, regulatory teams prepare submission content, and service teams document field issues, so a large share of operational effort sits in reading, interpreting, drafting, and checking evidence. That matters as the sector continues to grow, with medtech revenue expected to stabilize at 100 to 150 basis points above prepandemic rates [1], while broader life sciences outlooks estimate that AI implementation could support cost savings of up to 12% of total revenue within the next two to three years [2]. The opportunity is not only to move faster, but to reduce manual effort in work that already requires traceability and review.

That value does not come from placing a generic chatbot beside regulated work. It comes from embedding gen AI into the steps where people already make decisions, prepare records, and resolve exceptions. A regulatory affairs specialist, for example, can use gen AI to assemble a first draft of a submission response from approved source material, while the regulatory affairs reviewer confirms the wording before it enters the submission package. A quality engineer can receive a summarized complaint file with likely issue categories, which helps reduce triage time before the quality reviewer confirms the classification. In service operations, a field service coordinator can use AI to draft a case summary from prior notes, giving the service manager a clearer basis for follow-up.

For these examples to become buildable opportunities, medical technology organizations need to map gen AI at the function, process, and sub-process level before selecting tools or model features. That is where the work connects to specific systems, artifacts, owners, and controls. A complaint intake step may sit in a post-market surveillance system, depend on a complaint file, and require review by a quality reviewer, while a design change step may depend on a change control record and review by an engineering change board. When AI is mapped at this level, teams can see where it can safely reduce cycle time, where human review is mandatory, and where data readiness or system integration must be improved first.

This process-centric view also makes prioritization more practical. Instead of treating generative AI as a broad productivity layer, functions can compare opportunities by effort, risk, review burden, and measurable value. Drafting a design review summary may be a lower-risk starting point than supporting a production change, because the required evidence, reviewer, and release control are clearer. As a result, the AI roadmap becomes easier to govern, prioritize, and connect to operating outcomes.

This article uses a medical technology operating model to break work into functions. Each function is then divided into processes and sub-processes. For each area, it shows where AI can draft content and summarize records. A named human reviewer confirms production changes before release, and approves customer-facing messages or risk-bearing actions before they occur.

• How generative AI is transforming medical technology operations
• Why Gen AI use cases for medical technology must be mapped at the sub-process level
• Medical technology operating model and generative AI opportunity mapping across medical technology processes
• High-value generative AI use cases in medical technology
• How agentic AI works in medical technology workflows
• How to prioritize generative AI use cases in medical technology
• Governance, risk, and responsible AI in medical technology
• How ZBrain operationalizes generative AI use cases in medical technology
• Future of generative AI in medical technology

How generative AI is transforming medical technology operations

In medical technology operations, complaint handling often depends on evidence spread across service systems, customer emails, attachments, device history records, and prior quality events. Rule-based automation can support routing when required fields are available, and predictive models can identify similarity to past cases. However, these methods are less effective when critical evidence is embedded in narrative text, PDFs, or fragmented records.

Generative AI can summarize scattered complaint evidence into a traceable case narrative, while agentic workflows can retrieve relevant device history, service records, and prior event information for reviewer assessment. This helps complaint handling teams shorten triage, reduce manual evidence gathering, and improve the consistency of regulated review steps without replacing human accountability.

The same pattern extends beyond complaint intake. Across medical technology operations, many high-value workflows depend on fragmented evidence, regulated documentation, recurring reviews, and cross-functional handoffs. This is where generative and agentic AI can create practical value by helping teams assemble context, draft review-ready outputs, and route work through governed checkpoints.

• In document-heavy work, such as design history files, device master records, clinical evaluation reports, and supplier quality agreements, AI can help summarize evidence, reduce manual review effort, and make audit preparation more consistent.
• In narrative-heavy work, including complaint narratives, field service notes, adverse event summaries, and regulatory response drafts, AI-generated case language can give reviewers a clearer starting point and shorten response cycle times.
• In exception-heavy work, such as nonconformance investigations, corrective and preventive action escalations, supplier corrective action responses, and device history record discrepancies, AI can classify issues and package supporting evidence so quality teams spend less time searching for context and more time assessing risk.
• In knowledge-heavy work, including quality procedures, labeling rules, regulatory guidance, and risk management files, retrieval grounded in approved sources can reduce ambiguity and help teams interpret requirements more consistently.
• In workflow-heavy work, such as change control, post-market surveillance case assembly, regulatory submission readiness checks, and training impact assessments, agentic workflows can support governed routing, keep handoffs visible, and reduce delays between functions.

The design rule is practical: AI prepares the case by gathering relevant records, retrieves the evidence behind each suggested conclusion, and drafts the output so the right reviewer receives a complete work package rather than a blank task. Before any production change, customer-facing message, or risk-bearing action moves forward, a complaint handling reviewer, quality engineer, regulatory affairs reviewer, or change control board confirms the record and owns the decision. This operating model allows AI to create value in regulated medical technology operations by reducing manual effort, strengthening compliance, and keeping review accountability visible at every workflow step.

Why Gen AI use cases for medical technology must be mapped at the sub-process level

Medical technology workflows depend on specific records, artifacts, reviewers, and control points, so the value of gen AI becomes clear only when medical technology work is mapped at a lower level than the function level. Broad categories such as “AI for quality,” “AI for regulatory,” or “AI for product development” are useful for strategy, but they are too high-level to define source data, approval paths, risk controls, success metrics, or implementation scope.

A better approach is to map AI opportunities to the medical technology operating model:

Function: the major business, quality, regulatory, or product area, such as product development, quality assurance, regulatory affairs, post-market surveillance, clinical affairs, manufacturing, or supplier quality.

Process: the workflow area within that function, such as design control, complaint handling, change control, regulatory submission preparation, nonconformance management, CAPA, clinical evaluation, or supplier qualification.

Sub-process: the specific work activity, such as design and development plan update, requirements traceability matrix maintenance, usability engineering file readiness review, complaint narrative drafting, CAPA evidence assembly, or design history file completeness check.

AI-enabled opportunity: the specific way AI can support that sub-process, such as drafting controlled-document updates, summarizing evidence, classifying requirement links, identifying completeness gaps, retrieving approved records, or packaging review evidence.

This level of detail matters because medical technology workflows are tied to specific artifacts, systems, quality procedures, regulatory expectations, and accountable reviewers. A workflow for design and development plan authoring is different from one for requirements traceability maintenance. A usability engineering file readiness check is different from a device history record discrepancy review. A complaint narrative drafting workflow is different from a CAPA evidence assembly workflow.

For example, in design and development plan authoring and approval, AI can draft a proposed plan update based on approved inputs, while the product development manager confirms the controlled version. This shortens review preparation because stakeholders begin with a structured draft rather than reconciling comments across multiple working files.

In requirements traceability matrix maintenance, AI can classify proposed requirement links and flag gaps for a systems engineering reviewer to accept or reject. This reduces manual review effort and makes traceability issues visible before verification evidence is assembled.

In usability engineering file and human factors validation report readiness, AI can summarize completeness gaps across the usability engineering file and human factors validation report, while the human factors reviewer confirms readiness for formal review. This improves review accountability because open items are tied to the exact artifact that must be corrected.

By mapping AI opportunities at the sub-process level, medical technology organizations can move from broad AI concepts to executable workflows with defined inputs, review points, accountable owners, validation needs, and measurable outcomes. This structure also makes it clear where generative and agentic AI can assist, and where human confirmation must remain the control point.

Medical technology operating model and generative AI opportunity mapping across medical technology processes

The medical technology operating model below is organized into core industry-native functions that practitioners recognize. Each function is decomposed into its major processes and their sub-processes, and each sub-process carries the AI-enabled opportunity that applies to it. These opportunities are limited to software-based support, such as drafting, extraction, comparison, classification, summarization, and exception flagging, while accountable human reviewers remain responsible for approval, release, and any risk-bearing decision.

Function 1. Product development and design controls

Medical technology teams often lose time reconciling user needs, technical requirements, risk controls, verification evidence, and release records across long product lifecycles. This function owns concept translation through design transfer, including intended use, design inputs, design outputs, validation evidence, and the design history file.

Typical ownership sits with product management and systems engineering, with design quality and configuration management controlling release evidence. Generative and agentic AI help by retrieving, comparing, drafting, and routing governed review packs across product lifecycle management (PLM), electronic quality management system (eQMS), and clinical evidence platforms.

The highest-value opportunities for this function are requirements traceability and design-transfer evidence, because they require repeated reconciliation across PLM, eQMS, and controlled document repositories. Applying AI to retrieve, compare, draft exception summaries, and route gaps helps reduce manual effort, shorten design review cycles, and give the systems engineering lead a structured basis for release decisions.

Example agentic workflow: An example agentic workflow is the DHF completeness review. The workflow plans the completeness check, retrieves design and quality records from PLM and eQMS, drafts a gap register against 21 Code of Federal Regulations (CFR) 820.30 and ISO 13485, and routes exceptions to the design quality lead for disposition confirmation.

Function 2. Regulatory affairs and submissions

Regulatory affairs teams often face delayed submissions because evidence, labeling, change records, and registration data sit in separate systems. This function owns regulatory strategy, premarket pathway selection, submission content, regulator correspondence, and lifecycle change assessments for devices, in vitro diagnostic devices (IVDs), and software as a medical device (SaMD).

Submission managers and regulatory operations teams work across regulatory information management (RIM), PLM, eQMS, and enterprise resource planning (ERP) platforms. Generative and agentic AI help assemble dossiers, compare pathway evidence, extract source content, and route exceptions while final submission decisions stay with regulatory reviewers.

The highest-value opportunities for this function are submission assembly, labeling evidence alignment, and regulatory impact assessment. These are strong use cases because they are artifact-rich workflows with clear source systems. AI support helps reduce manual assembly effort, shorten the change-assessment cycle time, and keep final decisions with the submission manager, labeling lead, or regulatory affairs lead.

Example agentic workflow: An example agentic workflow is a 510(k) submission assembly workflow. The agent plans required 510(k) sections in the RIM platform, retrieve traceability and labeling evidence from PLM and eQMS repositories, draft cross-referenced text, and present readiness exceptions for the submission manager to confirm.

Function 3. Quality management, CAPA, and audit readiness

Quality teams often spend significant effort classifying quality events, chasing evidence, and preparing inspection files from disconnected systems. This function owns the quality management system, controlled procedures, corrective and preventive action (CAPA), nonconformance, deviations, inspection response, and quality management review.

Quality assurance, quality systems, document control, training, internal audit, and site quality roles work primarily across eQMS, governance, risk, and compliance (GRC), manufacturing execution system (MES), electronic device history record (eDHR), and PLM platforms. The quality management system regulation (QMSR) became effective on February 2, 2026³, increasing the need for traceable evidence and controlled review.

Highest-value opportunities for this function are CAPA intake, effectiveness checks, and audit preparation, because they combine high event volume with clear quality ownership. Gen AI support reduces manual triage and binder assembly, sharpens risk-based closure decisions, and improves inspection readiness without moving approval authority away from quality reviewers.

Example agentic workflow: An example agentic workflow is CAPA triage and evidence routing. The workflow plans risk-based triage, retrieves complaint and nonconformance evidence from quality systems, drafts an 8D investigation summary, and routes the package for CAPA owner priority confirmation.

Function 4. Clinical evidence and biostatistics

Clinical evidence teams often struggle to keep claims, study results, literature findings, and post-market evidence synchronized as products and standards change. This function owns evidence strategy, clinical investigation design, biostatistics, literature evidence, the clinical evaluation plan, and the clinical evaluation report (CER).

Clinical affairs, biostatistics, medical writing, data management, and clinical quality teams work across clinical evidence, RIM, eQMS, and analytics platforms. Generative and agentic AI help extract evidence, reconcile claims, summarize safety and performance data, and refresh post-market clinical follow-up (PMCF), post-market surveillance (PMS), and periodic safety update report (PSUR) content.

The highest-value opportunities for this function are literature screening, CER execution, and PMCF evaluation report preparation, because they are evidence-rich workflows with repeatable review gates. Gen AI support reduces manual abstraction, shortens evidence refresh cycles, and gives the clinical evaluator clearer accountability for confirming conclusions before regulatory use.

Example agentic workflow: An example agentic workflow is the CER and PMCF refresh workflow. The workflow plans the refresh from changed claims, retrieves study and surveillance evidence from controlled repositories, drafts updated CER and PMCF sections, and routes unsupported claims for clinical affairs reviewer confirmation.

Function 5. Post-Market surveillance and vigilance

Post-market teams often face high volumes of complaints, service notes, adverse event records, and literature signals that must be triaged consistently. This function owns the PMS system, complaint trends, vigilance reporting, corrections and removals, field safety notices, recall strategy, and escalation into CAPA, labeling, clinical, and regulatory workflows.

PMS leads, vigilance specialists, complaint investigators, medical safety, regulatory reporting, service quality, and field action teams work across complaint management, eQMS, customer relationship management (CRM), field service, and RIM platforms. Generative and agentic AI help convert unstructured inputs into consistent triage, investigation summaries, trend signals, and regulator-ready narratives while preserving human accountability for medical device reporting (MDR) decisions.

The highest-value opportunities for this function are complaint intake, MDR triage, and PMS report preparation, because they are high-volume workflows with structured source records and recurring narratives. Gen AI support reduces manual triage and report assembly effort, shortens regulatory decision cycles, and preserves accountability with the complaint investigator, vigilance specialist, or PMS lead.

Example agentic workflow: An example agentic workflow is MDR triage and eMDR drafting. The workflow plans the triage checklist, retrieves complaint and service evidence from controlled systems, drafts the reportability assessment, and prompts the regulatory reporting manager to confirm the final disposition.

Function 6. Manufacturing quality and electronic DHR review

Manufacturing quality teams often lose release time when lot records, deviations, nonconformances, and device master record revisions must be reconciled manually. This function owns production quality controls, electronic device history record review, lot release, shop floor deviations, process nonconformance, rework records, lot genealogy, and escalation into CAPA or engineering change.

Manufacturing quality engineers, production supervisors, quality inspectors, release reviewers, process engineers, MRB members, and site quality leads work across MES, eDHR, ERP, eQMS, and PLM platforms. Generative and agentic AI help summarize device history record (DHR) exceptions, reconcile lot history, compare production evidence with the device master record, and route release decisions to qualified reviewers.

The highest-value opportunities for this function are Electronic DHR review, exception triage, and MRB disposition, which stand out because they are high-volume workflows with clean review boundaries. Applying retrieval, classification, comparison, and drafting helps reduce record chasing, shorten lot-release cycles, and keep final decisions with the release reviewer or material review board.

Example agentic workflow: An example agentic workflow is the DHR exception-to-release workflow. The workflow plans the lot-release evidence check, retrieves DHR exceptions and device master record revisions, drafts a genealogy summary, and routes unresolved gaps for release reviewer approval or hold confirmation.

Function 7. Supplier quality, procurement, and supply chain controls

Supplier quality and procurement teams often need to evaluate supplier changes, quality events, and purchased material risks faster than manual comparison allows. This function owns supplier selection controls, supplier qualification, supplier audits, incoming inspection, component changes, procurement controls, supply risk, and distribution hold or release decisions.

Supplier quality engineers, category managers, incoming quality, supply planners, materials management, distribution quality, and supplier auditors work across ERP, eQMS, PLM, and eDHR platforms. Generative and agentic AI help compare supplier notifications, supplier corrective action request (SCAR) evidence, audit records, and component changes against specifications and risk criteria.

The highest-value opportunities for this function are supplier component change assessment, supplier 8D review, and distribution hold control, which offer a strong AI lift because they span supplier notifications, change records, SCARs, and lot evidence. These workflows reduce manual comparison effort, shorten release cycle time, and preserve accountability with the supplier quality manager, change control board, or distribution quality manager.

Example agentic workflow: An example agentic workflow is supplier component change assessment. The workflow plans the impact checklist, retrieves supplier notification and lot exposure evidence from controlled systems, drafts an impact summary, and records disposition only after change control board confirmation.

Function 8. Software engineering and SaMD lifecycle management

Software engineering teams often move faster than design control evidence can be reconciled, which creates release risk and audit exposure. This function owns software planning, SaMD and software in a medical device (SiMD) scope, IEC 62304 lifecycle evidence, software requirements, architecture, design, verification, validation, software release, software change control, and traceability to device design controls. Software engineering, systems engineering, software quality, product ownership, verification, release management, and design assurance teams work across PLM, eQMS, analytics, AI platform, and GRC platforms. Generative and agentic AI help keep agile delivery synchronized with V-model evidence, requirements traceability, software defects, test evidence, cybersecurity dependencies, and release packages

The highest-value opportunities for this function are software traceability, defect triage, and release package readiness, which are strong candidates because they recur in every sprint or release. AI support reduces evidence assembly time, improves release risk decisions, lowers rework cost, and strengthens compliance under the medical device software V-model.

Example agentic workflow: An example agentic workflow is the release evidence readiness workflow. The workflow plans the device master record release checklist, retrieves software and cybersecurity evidence from controlled repositories, drafts a gap-ranked release summary, and asks the release manager to confirm readiness.

Function 9. Device cybersecurity, privacy, and product security

Product security teams often need to connect threat models, vulnerability intelligence, privacy controls, and release evidence across fragmented repositories. This function owns product security strategy, cybersecurity risk assessment, threat modeling, software bill of materials (SBOM) governance, vulnerability monitoring, secure development evidence, privacy controls, and security commitments for connected device software. Product security, cybersecurity engineering, privacy, software quality, regulatory cybersecurity, security operations, and GRC teams work across security, PLM, eQMS, analytics, AI platform, and RIM systems. Generative and agentic AI help review threat models, summarize vulnerability intelligence, compare SBOM and software of unknown provenance (SOUP) records, and maintain auditable privacy and security evidence.

The highest-value opportunities for this function are vulnerability triage, SBOM governance, and cybersecurity labeling review, because they are high-volume, artifact-rich workflows with clear review boundaries. AI support reduces manual comparison effort across SBOMs, vulnerability advisories, risk records, and labeling content while final decisions remain with product security and regulatory cybersecurity reviewers.

Example agentic workflow: An example agentic workflow is vulnerability triage and remediation routing. The workflow plans triage steps, retrieves SBOM and vulnerability records from controlled security systems, drafts a remediation change record, and records confirmation by the product security lead.

Function 10. Medical affairs and professional education

Medical affairs teams often need to respond quickly to clinical questions while ensuring every statement remains aligned to approved evidence and instructions for use. This function supports scientific exchange, medical strategy, professional education, clinical claims support, medical information, field medical enablement, training content, and evidence communication. Medical affairs, professional education, clinical specialists, field medical teams, medical information, medical writing, and scientific review committees work across clinical evidence, CRM, eQMS, and RIM platforms. Generative and agentic AI help summarize approved evidence, draft reviewed response materials, align education content to instructions for use, and capture field insights for escalation.

The highest-value opportunities for this function are approved response management, claims mapping, and instructions for use aligned training content, because they reuse controlled evidence across medical information and education workflows. AI support reduces evidence lookup, shortens response and training-content cycle time, and gives reviewers structured packages for confirmation.

Example agentic workflow: An example agentic workflow is the approved medical response workflow. The workflow plans the response path for a clinician inquiry, retrieves labeling and clinical evidence from controlled repositories, drafts a referenced response with escalation flags, and records confirmation by the medical information manager.

Function 11. Market access and health economics

Market access teams often need to convert clinical evidence into payer, tender, and hospital value materials without drifting from approved labeling. This function owns value strategy, reimbursement evidence, health economics, payer evidence, tender support, value analysis committee support, and the translation of product claims into economic arguments. Market access, health economics and outcomes research (HEOR), reimbursement, pricing, clinical evidence, commercial strategy, and tender teams work across clinical evidence, analytics, CRM, RIM, and ERP platforms. Generative and agentic AI help extract evidence, assemble payer materials, check claims against intended use, and keep reimbursement content consistent.

The highest-value opportunities for this function are payer evidence dossiers, tender evidence packs, and claim consistency review, which are strong candidates because the same approved evidence is reused across access workflows. AI support reduces evidence collation, shortens response cycle time, and gives reviewers clearer traceability from economic arguments to labeling and clinical evidence.

Example agentic workflow: An example agentic workflow is payer evidence dossier assembly. The workflow plans the dossier checklist from the payer request, retrieves labeling and clinical evidence from controlled systems, drafts cited sections, and records market access director confirmation before release.

Function 12. Commercial marketing, sales enablement, and field operations

Commercial teams often need to produce field materials quickly while staying inside approved claims, labeling, and complaint referral rules. This function owns launch readiness, approved messaging, claims control, sales enablement, field training, account planning, commercial feedback, and coordination with medical, regulatory, quality, and service teams. Commercial marketing, product marketing, sales enablement, field sales, clinical sales specialists, commercial operations, and review committees work across CRM, RIM, eQMS, and analytics platforms. Generative and agentic AI help draft field materials, compare claims against labeling, summarize account feedback, and route promotional review packages.

The highest-value opportunities for this function are claims substantiation, promotional review routing, and CRM call note governance, which offer a strong AI lift because they combine high volume with artifact-rich evidence. AI support reduces manual assembly effort, shortens promotional approval cycle time, improves claim review quality, and strengthens compliance with final approval held by accountable reviewers.

Example agentic workflow: An example agentic workflow is a promotional claims review package. The workflow plans the review checklist, retrieves labeling and clinical evidence from controlled systems, drafts the substantiation package with unsupported wording flagged, and asks the promotional review committee chair to confirm disposition.

Function 13. Customer service and technical support

Customer service and technical support teams often need to distinguish routine service issues from complaints and adverse event signals under time pressure. This function owns issue intake, technical troubleshooting, field service coordination, service case documentation, complaint escalation, product returns, repair or replacement authorization, service trend review, and knowledge management. Customer service agents, technical support specialists, field service engineers, complaint coordinators, service quality, product support engineering, and returns teams work across CRM, field service, complaint management, ERP, and eQMS platforms. Generative and agentic AI help classify service notes, identify complaint signals, guide troubleshooting with approved content, summarize field service reports, and escalate quality-related cases consistently.

The highest-value opportunities are complaint classification, adverse event recognition, and field service report documentation. These are strong use cases because they combine high case volume with clear escalation boundaries. AI support reduces manual triage and documentation effort, shortens escalation cycle time, improves reportability decisions, and maintains confirmation with complaint and service quality reviewers.

Example agentic workflow: An example agentic workflow is complaint triage and MDR handoff. The workflow plans triage steps for a new service case, retrieves complaint and device history evidence from controlled systems, drafts the complaint summary, and records confirmation after the MDR specialist confirms reportability disposition.

Function 14. Technology, data, AI platform, and governance

Technology and data teams often need to support regulated AI use while maintaining validation, auditability, privacy, and system integration discipline. This function owns enterprise systems, data architecture, integrations, master data, analytics, GxP computer system validation, electronic records, e-signatures, cybersecurity controls, AI platform enablement, model governance, privacy controls, and AI risk governance. Enterprise architecture, data engineering, integration, analytics, platform engineering, validation, cybersecurity, privacy, GRC, and AI governance roles work across analytics, eQMS, PLM, RIM, MES, eDHR, ERP, CRM, clinical evidence, and security platforms. Generative and agentic AI help enable governed retrieval, drafting, extraction, classification, comparison, summarization, and workflow orchestration across fragmented medtech systems.

The highest-value opportunities are UDI and GUDID stewardship, validation evidence management, and AI risk control mapping, because they rely on standardized fields and clear evidence expectations. AI-enabled extraction, comparison, and summarization reduce reconciliation effort, shorten validation closure cycles, and strengthen compliance accountability.

Example agentic workflow: An example agentic workflow is Part 11 audit trail review. The workflow plans the monthly audit trail scope, retrieves DHR and change control logs from validated systems, drafts an exception summary with linked evidence, and captures final disposition confirmation from the quality systems manager.

High-value generative AI use cases in medical technology

In medical technology, the strongest generative and agentic AI candidates follow a repeatable pattern: high-volume entry points, existing artifacts, and fast confirmation by an accountable reviewer. This concentrates value where teams lose time to classification, evidence comparison, and document assembly, while keeping compliance judgment with the right function

A use case earns ‘high-value’ when its business impact is clear, and its review boundary is clean. The strongest candidates reduce manual review effort or shorten cycle time in a defined workflow, while preserving a clear human checkpoint before any production change, external communication, or risk-bearing decision.

How agentic AI works in medical technology workflows

Agentic AI is useful in medical technology when a workflow requires more than a single generated output. Many controlled processes involve multiple steps: identifying the required artifact, retrieving evidence from approved systems, checking gaps, preparing a draft package, routing exceptions, and waiting for an accountable reviewer to confirm the next action.

This is where agentic workflows differ from generative AI. Generative AI can draft a summary or response. Agentic AI can coordinate the surrounding workflow by using approved tools, following predefined rules, retrieving the right records, preparing review materials, and handing work to the correct role at the right control point.

In medical technology, this coordination must remain governed. The agent should not replace the quality, regulatory, clinical, or product owner. Its role is to reduce manual evidence assembly, improve consistency, and keep work moving through controlled procedures while preserving human approval for regulated decisions.

Here are some examples:

Design history file completeness review

Agent role: Plan and execute a design history file completeness check using the approved design and development plan.

• Retrieves requirements, risk evidence, verification records, and design review outputs from approved PLM or quality records.
• Compares available evidence against design control requirements and expected DHF sections.
• Drafts a gap register and reviewer pack for design quality review.
• Routes exceptions to the design quality lead, who confirms the disposition.

510(k) submission assembly workflow

Agent role: Support submission assembly by coordinating required evidence, draft sections, and readiness checks.

• Retrieves the requirements traceability matrix, design verification report, labeling evidence, and device description inputs from approved systems.
• Drafts cross-referenced section text using controlled source material.
• Flags missing labeling support, unresolved traceability gaps, or unsupported claims.
• Routes the package to regulatory operations, where the submission manager confirms readiness.

Corrective and preventive action triage and evidence routing

Agent role: Prepare CAPA triage materials from the intake record and related quality evidence.

• Retrieves complaint files, nonconformance records, device history records, and prior related events from approved quality systems.
• Classifies likely priority based on defined triage criteria.
• Drafts an investigation summary and supporting evidence pack for the CAPA queue.
• Routes the case to the CAPA owner, who confirms priority, scope, and next action.

Clinical evaluation and post-market follow-up refresh

Agent role: Support CER and PMCF refresh activities when claims, device performance evidence, or post-market signals change.

• Retrieves clinical evidence, PMCF findings, complaint trends, adverse event summaries, and benefit-risk inputs from approved sources.
• Compares new evidence against existing CER conclusions and supported claims.
• Drafts PMCF report sections and flags unsupported or outdated claim language.
• Routes evidence conclusions to the clinical affairs reviewer, who confirms final wording.

The control point is the review boundary. Agentic AI can plan work, retrieve evidence, draft materials, classify gaps, and route exceptions, but the accountable owner must confirm the decision before any controlled record, submission package, quality disposition, or production-related change moves forward.

How to prioritize generative AI use cases in medical technology

Generative AI prioritization in medical technology should focus on controlled sub-processes where evidence, documents, decisions, and review steps are clearly defined. Rather than building an inventory of broad ideas, teams should identify specific workflows where AI can reduce manual effort, improve consistency, and preserve reviewer accountability.

Start with bounded activities such as complaint narrative summarization, regulatory response drafting, DHF completeness review, or CAPA evidence assembly. Then score each candidate on business value, feasibility, data readiness, risk level, validation needs, and approval ownership before a quality assurance, regulatory affairs, clinical, or product reviewer approves the use case for implementation.

Avoid the four common stall patterns that slow GenAI adoption in medical technology: defining use cases at the incorrect level of workflow detail, selecting workflows without accessible source data, bypassing required governance and reviewer controls, and assigning quantified savings before the workflow has been validated. The strongest first projects are high-volume, artifact-rich sub-processes with clear source records, repeatable review steps, accountable owners, and measurable outcomes, such as complaint narrative summarization, DHF completeness review, CAPA evidence assembly, regulatory response drafting, or submission readiness checks.

Governance, risk, and responsible AI in medical technology

Governance is what makes AI usable in medical technology. Generative and agentic AI can support evidence review, documentation, classification, and workflow routing, but these capabilities must operate within defined quality, regulatory, clinical, and information security controls. In a regulated environment, the key question is not only what AI can produce, but which approved sources it can access, what it is allowed to draft or recommend, who reviews the output, and how the final decision is documented.

Responsible AI adoption, therefore, requires clear boundaries around data use, model behavior, reviewer accountability, validation, auditability, and change control. This ensures that AI improves speed and consistency without weakening design controls, quality system requirements, regulatory submission integrity, patient safety, or human decision ownership.

Human-in-the-loop (HITL) oversight: AI drafts, summarizes, or classifies; a designated reviewer role confirms the output before any production change, customer-facing message, or risk-bearing action at the industry’s key decision points. In design control planning, AI can prepare a design history file (DHF) completeness summary, but a design assurance reviewer confirms the disposition before the file is accepted. For intended use alignment or product classification, a regulatory affairs reviewer confirms the rationale before it shapes a premarket pathway, while a quality system owner approves any change that affects a design transfer package, customer-facing communication, or corrective and preventive action (CAPA) closure.

Regulatory and standards alignment: Regulatory and standards alignment: Lead with the medical technology regulatory and quality system anchors first, including FDA QMSR/21 CFR Part 820, ISO 13485, design controls, risk management, post-market surveillance, complaint handling, UDI/GUDID, 21 CFR Part 11 for electronic records and electronic signatures, and applicable FDA premarket pathways such as 510(k), De Novo, or PMA where relevant. For EU-market products, include the Medical Device Regulation, the In Vitro Diagnostic Medical Devices Regulation, and applicable post-market surveillance, vigilance, technical documentation, and quality management expectations. Use NIST AI RMF 1.0 and NIST AI 600-1 as cross-sector AI governance references for trustworthy AI, generative AI risk management, evaluation, monitoring, and control design. Treat the EU AI Act as an adjacent but increasingly relevant framework where AI-enabled medical devices, device software, or supporting AI systems fall into high-risk health or regulated product contexts.

Bias mitigation and evidence retention: In medical technology workflows, bias often appears as over-reliance on prior submissions, historical complaint language, familiar use scenarios, or previously accepted risk rationales. That can weaken intended-use assessment, hazard analysis, human factors review, or post-market signal interpretation if AI-assisted outputs are accepted because they sound consistent with past records rather than because they are supported by current evidence.

To control this risk, AI-assisted conclusions should remain traceable to named source artifacts. A regulatory affairs reviewer or risk management reviewer should confirm that the workflow retains the user needs specification, design input requirements, ISO 14971 risk management file, human factors validation report, complaint records, service records, clinical or performance evidence, and applicable labeling or IFU sources where relevant. This ensures each AI-assisted recommendation can be checked against approved evidence, documented rationale, and accountable reviewer judgment rather than model confidence alone.

Key governance requirements: Use-case inventory, risk tiering, approval gates, and monitoring, applied to this industry’s higher-risk sub-processes. The use-case inventory should record the workflow purpose, source systems, data sensitivity, reviewer role, and permitted output for each AI use in requirements traceability, verification package review, and CAPA root cause investigation. Risk tiering should place premarket submission authoring, risk control linkage, and design failure mode and effects analysis worksheet updates in higher-review categories because errors can affect regulatory strategy and patient safety. Approval gates and monitoring then give quality assurance a practical way to track low-confidence outputs, source conflicts, reviewer overrides, and recurring exceptions.

Design principles: AI workflows in medical technology should be grounded in approved sources, constrained by access controls, and designed around human confirmation before any regulated or customer-facing action proceeds. Retrieval should come from controlled medical technology sources such as the electronic quality management system (EQMS), product lifecycle management (PLM) records, regulatory information management data, and controlled design files, rather than open-ended memory. Least privilege and role-based access control should limit retrieval to records the user is authorized to access, while scoped tool access should allow an agent to draft a change assessment without releasing the change. Human confirmation remains the final control before any record update, content submission, or customer-facing response moves forward.

Traceability and data security: AI-assisted workflows in medical technology should preserve a complete, reviewable record of how each output was produced and protect the regulated data used to produce it. The audit trail should capture prompts, source artifacts, retrieved excerpts, model version, reviewer disposition, approvals, and any resulting system action so auditors can reconstruct how a DHF index update, requirements traceability matrix change, CAPA summary, or post-market review output was generated.

Those records should be reviewable under applicable controls for electronic records and electronic signatures, the Quality Management System Regulation, ISO 13485, NIST CSF 2.0, ISO/IEC 27001, and SOC 2 Type II, where relevant. Data protection should cover design intellectual property, clinical and performance evidence, complaint records, service records, supplier quality information, and other regulated product data. This traceability and security foundation allows teams to shorten review cycles while preserving evidence quality, access control, and compliance accountability.

How ZBrain operationalizes generative AI use cases in medical technology

Identifying use cases is only the first step. Medical technology organizations also need a way to design, build, validate, deploy, govern, and scale AI workflows across functions. This is where ZBrain helps.

ZBrain is an end-to-end AI enablement platform that provides enterprises with a structured pathway from identifying where artificial intelligence can deliver value to deploying it as a governed, scalable capability. The platform operates across two core dimensions: strategy and execution. In the strategy phase, ZBrain helps organizations identify, evaluate, and design AI solutions by leveraging their own business processes, technology landscape, and operational data. The execution phase ensures these AI opportunities are systematically developed into scalable solutions. By covering the full AI lifecycle in six connected stages, ZBrain enables each initiative to progress from strategic insight to enterprise deployment, eliminating fragmented efforts.

Preparation (foundation)

Establishes a comprehensive understanding of the organization’s current enterprise environment, including processes, technology systems, workforce metrics, and KPIs, providing the insight needed to identify where AI can deliver meaningful value.

Ideation & prioritization (discovery)

Leverages enterprise data to identify AI opportunities and then prioritizes them based on feasibility, cost, benefits, and potential ROI, with priority given to those that can be embedded within existing processes.

Solution design (validation)

Translates prioritized opportunities into ROI-validated and KPI-mapped solution design blueprints, defining where AI can assist, augment, or act autonomously within workflows.

Technical design (Build-Ready)

Transforms solution requirements into structured, build-ready technical design artifacts, including architecture diagrams, schemas, agentic workflows, user stories, epics, and business requirement documents. This provides the build team with a complete technical design to serve as a foundation for development.

Proof of concept / PoC (validation)

Tests selected AI solutions in controlled environments to validate feasibility, business value, and implementation readiness before scaling.

Scaled product

Scale validated proof-of-concept, supported by performance metrics and observability data, are deployed as governed, production-grade AI solutions across enterprise environments, with continuous improvement loops to sustain impact.

Future of generative AI in medical technology

Medical technology work is still slowed by evidence scattered across design files, quality records, clinical documentation, and regulatory correspondence, so the first trajectory is a shift to federated platforms with shared orchestration, governance, observability, and integration. Instead of placing separate copilots inside each function, medtech organizations can give regulatory affairs, quality, and clinical teams a common control layer while keeping approved data access tied to each function’s responsibilities. In practice, a system might draft a regulatory impact summary from controlled source material and show which records supported each conclusion, which reduces manual reconciliation and gives a regulatory affairs reviewer a clear basis to confirm any submission-related change before it moves forward. That platform foundation matters because it turns scattered AI assistance into governed work coordination, and it sets up the next phase of more durable agentic workflows.

Once the shared control layer is in place, the next trajectory is the rise of long-horizon agentic workflows that stay active across multi-step goals rather than answering one prompt at a time. A postmarket surveillance workflow, for example, may need to connect a complaint narrative with prior investigations and a draft trend assessment, so an agent can maintain context across the review packet while a complaint handling manager confirms classifications and a medical safety reviewer confirms any risk-bearing conclusion. The value is not that AI acts on its own. It is that the workflow keeps the case moving, highlights missing evidence, and prepares reviewable drafts so that specialists spend less time assembling files and more time applying judgment. As these workflows become more persistent, the harder question shifts from whether a model can draft a useful passage to whether the process itself has been designed well enough to govern the draft.

That shift defines the third trajectory: workflow design becomes more important than model selection as frontier models such as Claude 4.6, Gemini 3.1, and GPT-5.5 converge on core drafting, summarization, and reasoning capabilities. Medtech functions will still evaluate model performance, but lasting value will come from clearer review gates, better source controls, and tighter integration with the electronic quality management system (eQMS). A regulatory information management (RIM) platform also becomes more useful when AI outputs are routed through defined ownership, because a regulatory operations reviewer can verify the proposed update before any external filing or customer-facing communication is changed. In the next few years, the strongest medical technology AI programs are likely to look less like collections of generic assistants and more like governed workflow systems, built around the documents, decisions, and accountability structures that already determine product quality and regulatory confidence.

Endnote

Medical technology work is constrained by evidence, approvals, and regulatory expectations, so broad claims about AI are not enough. This article uses the operating model as the anchor, moving from function to process to sub-process, and positioning generative and agentic AI only where the work is specific enough to validate and review. The distinction matters because value emerges when AI reduces manual document effort, improves evidence comparison, or strengthens a defined review point, not when it is treated as a generic layer across the business.

The clearest opportunities sit in artifacts and systems that medical technology teams already govern. A model can draft a design and development plan, which reduces blank-page effort while a design quality reviewer remains responsible for approval. It can summarize the reasoning inside a verification report package or extract trace links from product lifecycle management records, so the verification lead reviews a shorter, better-organized record. In adjacent checks, it can classify evidence gaps in the design history file and compare intended use wording with indications for use, with a regulatory affairs reviewer confirming any output before a production change, customer-facing message, or risk-bearing action.

That is also the right way to choose early projects. The better candidates are high-volume, artifact-rich sub-processes with clean handoffs and a known reviewer, then scored for business value and delivery feasibility. Requirements traceability matrix maintenance fits that pattern because proposed link updates can be generated from existing evidence, and a systems engineering reviewer can confirm them before the controlled matrix changes. This keeps the first wave tied to faster cycle time, lower manual effort, and clearer review accountability.

Governance needs to be designed into that pattern from the start. Within the US regulatory and assurance frame, the National Institute of Standards and Technology AI Risk Management Framework (NIST AI RMF) gives teams a shared language for AI risk oversight, while medical technology standards reinforce traceability from user needs through risk controls. Each model output should leave an audit trail that shows the source evidence and reviewer role, while also recording the final disposition.

As agentic workflows mature, the model extends from a single drafted artifact to a governed sequence that gathers source records and prepares the next proposed step. The boundary does not move. The risk management owner or design quality reviewer still confirms the result before it affects controlled work. The durable advantage goes to medical technology teams that map AI to named sub-processes, keep human accountability visible, and scale only the workflows that prove value under control.

Turn medical technology AI opportunities into scalable solutions with ZBrain. Identify high-value workflows, map sub-processes, validate fit, and scale AI across key functions. Contact the ZBrain team today!